Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant851 active trials17 approved drugs339 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,880 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT05138146 | A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma | unknown | Phase 2 | 70 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Nov 30, 2021 |
| clinicaltrials |
| NCT01294670 | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Nov 18, 2021 | clinicaltrials |
| NCT00972335 | Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma | terminated | Phase 2 | 18 | SCRI Development Innovations, LLCOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT00000996 | A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 2 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00000687 | Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 2 | 60 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00001114 | The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma | completed | Phase 2 | 90 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 2 | Nov 1, 2021 | clinicaltrials |
| NCT02247544 | Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma(TRAVELL) | completed | Phase 2 | 105 | Italian Sarcoma GroupNETWORK | 1 | Nov 1, 2021 | clinicaltrials |
| NCT00000807 | Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy | completed | Phase 2 | 41 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 28, 2021 | clinicaltrials |
| NCT04933669 | Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors(ZJGIST-01) | recruiting | Phase 2 | 122 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02261207 | Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor | completed | Phase 2 | 17 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02808247 | Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma(ANITA) | terminated | Phase 2 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 20, 2021 | clinicaltrials |
| NCT01913652 | Ph II Cabazitaxel DD Liposarcoma | completed | Phase 2 | 42 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 14, 2021 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT01010308 | Nadolol for Proliferating Infantile Hemangiomas | completed | Phase 2 | 20 | The Hospital for Sick ChildrenOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT02732015 | Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy | terminated | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT02216578 | Ph II CABOGIST in GIST | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 15, 2021 | clinicaltrials |
| NCT01441635 | Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids | completed | Phase 2 | 271 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jul 13, 2021 | clinicaltrials |
| NCT02181829 | Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT01275222 | Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Jun 25, 2021 | clinicaltrials |
| NCT02691026 | A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery | terminated | Phase 2 | 8 | Oslo University HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04910126 | Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma | unknown | Phase 2 | 84 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02888665 | Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT04886765 | A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | unknown | Phase 1 / Phase 2 | 238 | AlaMab Therapeutics (Shanghai) Inc.INDUSTRY | 0 | May 14, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01759303 | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | terminated | Phase 2 | 12 | Emerald Clinical Inc.INDUSTRY | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02379845 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | completed | Phase 2 / Phase 3 | 180 | NanobiotixINDUSTRY | 13 | Apr 6, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01140737 | A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas(Axi-STS) | completed | Phase 2 | 145 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01276236 | Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) | completed | Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT02448537 | A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03623581 | Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) | unknown | Phase 2 | 35 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT04765228 | Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 45 | Yong ChenOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04761172 | NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours | unknown | Phase 2 / Phase 3 | 10 | Leiden University Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT00642941 | A Study of R1507 in Participants With Recurrent or Refractory Sarcoma | terminated | Phase 2 | 317 | Hoffmann-La RocheINDUSTRY | 11 | Feb 3, 2021 | clinicaltrials |
| NCT01833520 | Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma | completed | Phase 1 / Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03989596 | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas(SINDIR) | unknown | Phase 2 | 30 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01543802 | Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma(NOPASS) | terminated | Phase 2 | 21 | Heidelberg UniversityOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT01876043 | Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial(APLIPO) | terminated | Phase 2 | 24 | Institut BergoniéOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT01125046 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | completed | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03651375 | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall(UN-RESARC) | unknown | Phase 2 | 46 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03620149 | Reduced Dose-density of Denosumab for Unresectable GCTB(REDUCE) | terminated | Phase 2 | 2 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 6, 2021 | clinicaltrials |
| NCT01643850 | MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 2 | Jan 5, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Dec 7, 2021source: clinicaltrials